Lobe Sciences (FRA:LOBE) EPS (Basic) : €-0.02 (TTM As of Feb. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Lobe Sciences EPS (Basic)?

Lobe Sciences's basic earnings per share (Basic EPS) for the three months ended in Feb. 2025 was €0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2025 was €-0.02.

Lobe Sciences's EPS (Diluted) for the three months ended in Feb. 2025 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2025 was €-0.02.

Lobe Sciences's EPS without NRI for the three months ended in Feb. 2025 was €0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2025 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Lobe Sciences EPS (Basic) Historical Data

The historical data trend for Lobe Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences EPS (Basic) Chart

Lobe Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

EPS (Basic)

Get a 7-Day Free Trial

-0.19

-0.03

-0.25

-0.03

Lobe Sciences Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-	-0.01	-	-

Lobe Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lobe Sciences's Basic EPS for the fiscal year that ended in Aug. 2024 is calculated as

Basic EPS (A: Aug. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.937	-	0)	/	122.134
	=	-0.02

Lobe Sciences's Basic EPS for the quarter that ended in Feb. 2025 is calculated as

Basic EPS (Q: Feb. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.472	-	0)	/	186.368
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02

Lobe Sciences (FRA:LOBE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lobe Sciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lobe Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (FRA:LOBE) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

LOBEF:USA LOBE:Canada

Address

1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7

Website

https://www.lobesciences.com

Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.

Lobe Sciences Headlines

No Headlines